Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Comparison Visfatin level between Obese and Non Obese, Hypertensive and Normotensive Patients with Ischemic Heart Disease


Affiliations
1 Department of the Pathological Analysis Techniques, College of Al-Toosi University Najaf, Iraq
2 Technical Institute of AL-Diwaniyah, AL-Furat AL-Awsat Technical University, Najaf, Iraq
     

   Subscribe/Renew Journal


In the current study, seventy of patients who suffering of IHD and the control group was composed of 20 healthy. The samples were collected from the Coronary Care Unit (CCU) in Al-Sadder Teaching Hospital in Al-Najaf province/ Iraq, during the period from September till December 2018. The ages of patients and control ranged from 30 to 69 years old. The Patients groups are divided into subgroup according blood pressure and Body mass index. The results of current study revealed significant differences between IHD group and healthy group, significantly increased (p<0.05) in serum visfatin level and W.C., BMI compared with healthy group. The results indicated a significant increased (p<0.05) in serum VF level of hypertensive group compared with normotensive group in IHD patients. The results indicated when compared with different BMI (normal, over, obese and morbid weight) groups of IHD, there was a significant increase (p>0.05) in VF concentration among different BMI. The result indicated positive correlation between BMI, W.C.) and (VF). Conclusion: The current study concluded that visfatin level were good marker for detection and diagnosis of ischemic heart disease, and visfatin highly related with risk factors of ischemic heart disease such as hypertensive blood pressure and obesity.

Keywords

Ischemic Heart Disease, Visfatin , Obesity and Hypertension.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Kumar, V.; Abbas, AK.; Fausto, N. and Mitchell, R.N. Robbins Basic Pathology. (8th ed.) Philadelphia: Saunders, 2007.

  • Rydén, L.; Standl. E.; Bartnik, M.; Van den Berghe, G.; Betteridge J.; de Boer. M.J.; Cosentino, F. and Jönsson, B. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur. Heart J. 2007; 28, 88-136.

  • Kaur, J. A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice, 2014; 21 pages.

  • Vitale, C.; Miceli, M. and Rosano, G.M. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric. 2007; 10:16–20.

  • Naveen, G. A study of lipid profile in smokers and it is association in ischemic heart disease, Dissertation, M.D. (General Medicine), 2009; P39.

  • National Heart Foundation of Australia. (NHFA). (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension, NHFA Journal, 2008.

  • American Heart Association (AHA). Risk factors and coronary heart disease. American Heart Association Journal, 2010.

  • Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M. and et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005; 307: 426-430.

  • Samal, B.; Sun, Y.; Stearns, G.; Xie, C.; Suggs, S. and McNiece, I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology, 1994; 14 (2):1431–7.

  • Curat , C.A.; Wegner, V.; Sengenes, C,.; Miranville, A.; Tonus, C.; Busse, R. and et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia,2006; 49(4): 744-747.

  • Garten, A.; Petzold, S.; Barnikol-Oettler, A.; Korner, A.; Thasler, W.E.; Kratzsch, J. and et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochemical and Biophysical Research Communications, 2010; 391(1):376–81.

  • Costford, S.R.; Bajpeyi, S.; Pasarica, M.; Albarado, D.C.; Thomas, S.C.; Xie, H. and et al. Skeletal muscle NAMPT is induced by exercise in humans. American Journal of Physiology – Endocrinology and Metabolism, 2010; 298(1): 117–26.

  • Filippatos, T.D.; Tsimihodimos, V.; Derdemezis, C.S.; Gazi, I.F.; Saougos, V.; Mikhailidis, D.P. and et al. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr. Metab. Cardiovasc. Dis. 2013; 23:330-6.

  • Omer, R. and Mahmood, M. Correlation between Visfatin and Creatine Kinase Levels with Periodontal Health Status of Patients with Coronary Atherosclerosis and Chronic Periodontitis. J. Bagh. Coll. Dentistry, 2016; 28(3):121-125.

  • Sethi, J.K. and Vidal-Puig, A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med., 2005; 11:344-7.

  • Spiroglou, S.G.; Kostopoulos, C.G.; Varakis, J.N. and Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 2010; 17:115-30.

  • Sommer, G.; Garten, A.; Petzold, S. and et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. (Lond), 2011; 115:13-23.

  • Zhang, L.Q.; Heruth, D.P. and Ye, S.Q. (2011). Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 3:13-25.

  • Kong, Q.; Xia, M.; Liang, R.; Li, L.; Cu, X. et al. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med. J. 2014; 55(7): 383-387.

  • Curat , C.A.; Wegner, V.; Sengenes, C,.; Miranville, A.; Tonus, C.; Busse, R. and et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia,2006; 49(4): 744-747.

  • Leclercq, I.; Da Silva, A.; Schroyen, B.; Van Hul, N.; Geerts, A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J. Hepatol. 2007; 47(1): 142-156.

  • Ooi, S.Q.; Chan, R.M.; Poh, L.K.; Loke, K.Y.; Heng, C.K.; Chan, Y.H. and et al. Visfatin and its genetic variants are associated with obesityrelated morbidities and cardiometabolic risk in severely obese children. Pediatr. Obes. 2013.

  • Vanhoutte, P.M. Endothelial dysfunction : the first step toward coronary arteriosclerosis. Circulation, 2009; 73(4): 595-601.

  • Johnston, T.P. . Poloxamer 407 as a general lipase inhibitor: its implications in lipid metabolism and atheroma formation in C57BL/6 mice. J. Pharm. Pharmacol. 2010; 62:1807-12.

  • Gürsoy, M.; Duygu, E.; Hökenek, A.F.; Gülcan, F. and Kınoğlu, B. Serum Visfatin Levels and Coronary Artery Disease. Koşuyolu Heart Journal, 2014; 17(2):95-99.

  • Ganguli, D.; Das, N.; Saha, I.; Sanapala, K.R.; Chaudhuri, D. Ghosh, S. and Dey, S. Association between Inflammatory Markers and Cardiovascular Risk Factors in Women. Department of Physiology, University College of Science and Technology, 2010; 1-8.

  • Sanchez-Viveros, S.; Barquera, S.; Medina-Solis, C.E.; Velazquez-Alva, M.C. and Valdez, R.. Association between diabetes mellitus and hypertension with anthropometric indicators in older adults: results of the Mexican Health survey. J. Nutr. Health Aging,2008; 12(5): p327.

  • Shidfar, F.; Alborzi, F.; Salehi, M. and Nojomi, M. Association of waist circumference, body mass index and conicity index with cardiovascular risk factors in postmenopausal women. Cardiovasc. J. Afr. 2012; 23 (8): 442–445.

  • Sadeghi, M.; Pourmoghaddas, Z.; Hekmatnia, A.; Sanei, H.; Tavakoli, B.; Tchernof, A. et al. Abdominal fat distribution and serum lipids in patients with and without coronary heart disease. Arch. Iran Med. 2013; 16(3): 149 – 153.

  • Pouliot, M.C.; Desprqs, J.P.; Lemieux, S.; Moorjani, S.; Bouchard, C.; Tremblay, A. and et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol.,1994; 73(7): 460 – 468.

  • Mazaherioun, M.; Hosseinzadeh-Attar, M.J.; Janani, L.; Vasheghani Farahani, A.; Rezvan, N.; Karbaschian, Z. and et al. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch. Iran Med. 2012; 15(11): 688 – 692.

  • Berndt, J.; Klöting, N.; Kralisch, S.; Kovacs, P.; Fasshauer, M.; Schön, M.; Stumvoll, M. and Blüher, M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes,2005; 54: 2911-2916.

  • Sonoli, S.S.; Shivprasad, S.; . Prasad, C.; Patil, A.; Desai, P.; M.S. and Somannavar , M. Visfatin – a review. European Review for Medical and Pharmacological Sciences, 2011; 15: 9-14.

  • Manco, M.; Fernandez-Real, J.; Equitani, F.; Vendrell, J.; Valera Mora, Me. and et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J. Clin. Endocrinol. Metab. 2007; 92: 483-490.

  • Haider, D.; Schindler, K.; Schaller, G.; Prager , G.; Wolzt, M.; Ludvik, B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab., 2006; 91: 1578-1581.


Abstract Views: 267

PDF Views: 0




  • Comparison Visfatin level between Obese and Non Obese, Hypertensive and Normotensive Patients with Ischemic Heart Disease

Abstract Views: 267  |  PDF Views: 0

Authors

Wijdan Rajh Hamza Al-Kraity
Department of the Pathological Analysis Techniques, College of Al-Toosi University Najaf, Iraq
Murtadha M. Jawad
Technical Institute of AL-Diwaniyah, AL-Furat AL-Awsat Technical University, Najaf, Iraq

Abstract


In the current study, seventy of patients who suffering of IHD and the control group was composed of 20 healthy. The samples were collected from the Coronary Care Unit (CCU) in Al-Sadder Teaching Hospital in Al-Najaf province/ Iraq, during the period from September till December 2018. The ages of patients and control ranged from 30 to 69 years old. The Patients groups are divided into subgroup according blood pressure and Body mass index. The results of current study revealed significant differences between IHD group and healthy group, significantly increased (p<0.05) in serum visfatin level and W.C., BMI compared with healthy group. The results indicated a significant increased (p<0.05) in serum VF level of hypertensive group compared with normotensive group in IHD patients. The results indicated when compared with different BMI (normal, over, obese and morbid weight) groups of IHD, there was a significant increase (p>0.05) in VF concentration among different BMI. The result indicated positive correlation between BMI, W.C.) and (VF). Conclusion: The current study concluded that visfatin level were good marker for detection and diagnosis of ischemic heart disease, and visfatin highly related with risk factors of ischemic heart disease such as hypertensive blood pressure and obesity.

Keywords


Ischemic Heart Disease, Visfatin , Obesity and Hypertension.

References